Latent TGF-beta 2

Latent TGF-beta 2 Molekülinformation

Englischer Name	Transforming growth factor beta 2	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	6	Target-Alias	TGF-beta-2，BSC-1 Cell Growth Inhibitor，Polyergin，Glioblastoma-Derived T-Cell Suppressor Factor，Cetermin，LDS4，TGFB2，Transforming Growth Factor， Beta 2，Transforming Growth Factor Beta-2 Proprotein，TGF-Beta2，Transforming Growth Factor Beta 2，G-TSF，Transforming Growth Factor beta2，LAP，Prepro-Transforming Growth Factor Beta-2
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Transforming growth factor beta 2
Target-Alias	TGF-beta-2，BSC-1 Cell Growth Inhibitor，Polyergin，Glioblastoma-Derived T-Cell Suppressor Factor，Cetermin，LDS4，TGFB2，Transforming Growth Factor， Beta 2，Transforming Growth Factor Beta-2 Proprotein，TGF-Beta2，Transforming Growth Factor Beta 2，G-TSF，Transforming Growth Factor beta2，LAP，Prepro-Transforming Growth Factor Beta-2
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	6
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Latent TGF-beta 2 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TG2-H5243	Human	HEK293	Human Latent TGF-beta 2 / TGFB2 Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

Latent TGF-beta 2 Molekülhintergrund

Transforming growth factor beta 2 ( TGFB2) is also known as TGF-β2, G-TSF, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB2 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB2 protein can inhibit the T cell growth by IL-2-dependent. and can inhibit immune surveillance during tumor development, the protein promoting tumor growth with an autocrine manner. TGF-β2 can affect the viability of killer cells and reduce the expression of IL-2, IL-6, IL-10, IFN-γ and other cytokines.TGFB2 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages.

Latent TGF-beta 2 Molekülalias

Latent TGFB2,MGC116892,TGFβ2,TGF-beta2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Trabedersen	AP 2/09-DS; AP-12009; OT-201; AP-2/09; AP-2/09-DS; OT-101	Phase 3 Clinical	Isarna Therapeutics Gmbh	Astrocytoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Diffuse Intrinsic Pontine Glioma; Glioblastoma; Lung Neoplasms; Melanoma; Mesothelioma; Pancreatic Neoplasms; Solid tumours	Details
Bintrafusp alfa	M-7824; GSK-4045154; MSB-0011359C	Phase 3 Clinical	Merck Serono	Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop	Details
Nisevokitug	NIS-793	Phase 3 Clinical	Xoma Corp	Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential	Details
ISTH-0036	ISTH-0036	Phase 2 Clinical	Isarna Therapeutics Gmbh	Diabetic macular oedema; Glaucoma, Open-Angle; Wet Macular Degeneration	Details
Tosposertib phosphate	TU-2218; NCE401; NCE-401	Phase 2 Clinical	TiumBio Co Ltd	Idiopathic Pulmonary Fibrosis; Solid tumours	Details
LP-008	LP-008	Phase 1 Clinical	Lepu Biopharma Co Ltd	Solid tumours	Details